真实世界中生物制剂初治患者应用阿普司特或生物制剂治疗银屑病的美国医疗成本。
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
机构信息
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Celgene Corporation, Summit, NJ, USA.
出版信息
J Comp Eff Res. 2019 Jan;8(1):45-54. doi: 10.2217/cer-2018-0097. Epub 2018 Nov 2.
AIM
Biologics and apremilast have advanced psoriasis management by adding treatment options. This study evaluated persistence, adherence and healthcare costs among biologic-naive patients receiving apremilast or biologics.
METHODS
Administrative claims data for adults starting apremilast or biologics from 1 January 2013 to 30 June 2016 were matched based on demographics.
RESULTS
Apremilast (n = 703) and biologics (n = 1378) had similar baseline characteristics. 12-month persistence and adherence rates were similar. Adjusted total healthcare costs were lower with apremilast versus biologics (p < 0.001) due to lower total outpatient pharmacy costs (p < 0.001).
CONCLUSION
Real-world apremilast users had similar adherence and lower total healthcare costs versus biologic users. Apremilast's cost advantage was evident regardless of whether the patients were persistent or nonpersistent, or switched or did not switch treatments.
目的
生物制剂和阿普米司特通过增加治疗选择，推进了银屑病的治疗管理。本研究评估了初治患者接受阿普米司特或生物制剂治疗的药物持久性、治疗依从性和医疗保健费用。
方法
从 2013 年 1 月 1 日至 2016 年 6 月 30 日，根据人口统计学特征，对使用阿普米司特或生物制剂的成年人的行政索赔数据进行匹配。
结果
阿普米司特（n=703）和生物制剂（n=1378）具有相似的基线特征。12 个月的药物持久性和治疗依从性率相似。由于总门诊药房费用较低（p<0.001），与生物制剂相比，阿普米司特的调整后总医疗保健费用较低（p<0.001）。
结论
与生物制剂使用者相比，真实世界中使用阿普米司特的患者具有相似的治疗依从性和更低的总医疗保健费用。无论患者是否持续治疗、是否换药，阿普米司特的成本优势都很明显。
Zotero 插件